title: Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
authors.affiliation: Department of Cardiology, Methodist DeBakey Heart and Vascular Center, Methodist Research Institute, Houston, Texas, USA. cpratt@tmhs.org
authors.forename: Craig M
authors.initials: CM
authors.lastname: Pratt
authors.forename: Denis
authors.initials: D
authors.lastname: Roy
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.forename: D George
authors.initials: DG
authors.lastname: Wyse
authors.forename: Egon
authors.initials: E
authors.lastname: Toft
authors.forename: Steen
authors.initials: S
authors.lastname: Juul-Moller
authors.forename: Enrique
authors.initials: E
authors.lastname: Retyk
authors.forename: David Humphrey
authors.initials: DH
authors.lastname: Drenning
mesh_terms: D000840:Anisoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001282:Atrial Flutter / Q000188:drug therapy / Q000503:physiopathology; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D011759:Pyrrolidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D010919:Placebos; D011759:Pyrrolidines; C524581:vernakalant